Teva Revises FY23 Revenue Forecast To $15.0B-$15.4B From $14.8B-$15.4B Vs. Consensus Of $15.02B; Maintains Adjusted EPS Forecast Of $2.25-$2.55 Vs. Consensus Of $2.27
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical Industries Ltd. has revised its FY23 revenue forecast to $15.0B-$15.4B, up from the previous range of $14.8B-$15.4B. The new forecast is in line with the consensus estimate of $15.02B. The company has maintained its adjusted EPS forecast of $2.25-$2.55, which is also in line with the consensus estimate of $2.27.
August 04, 2023 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva's upward revision of its FY23 revenue forecast is a positive signal for investors. The new forecast aligns with the consensus estimate, indicating that the company is on track to meet market expectations.
Teva's upward revision of its FY23 revenue forecast indicates that the company is performing well and expects to continue doing so in the future. This is likely to boost investor confidence and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100